Woo V, et al. - In usual clinical practice in Canada, researchers assessed the effectiveness and safety of canagliflozin (CANA), an orally active sodium-glucose co-transporter 2 inhibitor (SGLT2i), among 527 SGLT2i-naïve adult patients with type 2 diabetes mellitus. Study participants were on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7% and had an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m². These participants received CANA as part of their usual treatment approach, and were followed for 12 months. Regardless of duration of diabetes or background AHA treatment regimen, a significant improvement from baseline in mean HbA1c levels was noted at 6 months and at 12 months. At 12 months, significant reductions in systolic blood pressure, body weight, waist circumference, and body mass index were also observed. In real-world clinical practices in Canada, CANA treatment was effective in the optimal management of type 2 diabetes mellitus. There were no reported unexpected adverse events.